

**MINUTES OF THE MEETING OF THE CUMBRIA AREA PRESCRIBING COMMITTEE
HELD ON THURSDAY 13th AUGUST, 2015 AT 2.00PM
ENTERPRISE HOUSE, KENDAL**

Present:	Bill Glendinning Lesley Angell Pauline Bourne Andrea Loudon Ben Merriman Dr Andrea Mulgrew Sarah Roberts Dr Julia Smith Dr Amanda Pugh Phil Utting	Chief Pharmacist, NCUHT (Chair) Medicines Optimisation Team Lead, NECS Senior Pharmacist, UHMBT Clinical Pharmacy Lead, CCG LPC Representative GP Prescribing Lead, Allerdale Locality Patient Voice representative GP Prescribing Lead, South Lakes Locality GP Prescribing Lead, Furness Locality Senior Technician, Medicines Optimisation, NECS
----------	---	--

In Attendance: Christine Nicholson	Admin Assistant, NECS
------------------------------------	-----------------------

25/15 **APOLOGIES FOR ABSENCE** *Action*

Apologies for absence were received from:
 Helen Huck, Lead Pharmacist CPFT
 Catherine Bousfield

26/15 **DECLARATION OF INTERESTS**

None

27/15 **MINUTES OF THE PREVIOUS MEETING**

The minutes of the previous meeting held on 11th June, 2015 were agreed.

28/15 **ACTION LOG FROM PREVIOUS MEETING (11th June 2015)**

Updates were given as follows:

- 14/026 – This action was completed
- 14/041 – This action was completed
- 14/044 – This action was completed
- 14/050 – This action was completed
- 15/01 – This action was completed
- 15/07 – This action was completed
- 15/08 – This action was completed
- 15/12 – This action was completed
- 15/17 – This action was completed
- 15/18 – This action was completed
- 15/19 – This action was completed
- 15/21 – This action was completed
- 15/22 – This action was completed
- 15/24 – This action was completed
- 15/25 – This action was completed
- 15/26 – This action was completed

69/14 – DMARDS Monitoring ONGOING.	PB/BG
70/14 – Revised Dosing for Domperidone use in babies and children position statement ACTION: Manchester Paediatric Consultant now drafting guideline for approval. No timescale at present. ONGOING.	PB
85/14 – Primary Care Management of Cellulitis Waiting for feedback from July 2015 meeting. ONGOING.	AL
107/14 & 19/15 – Comments on Draft PPI's Algorithm Updated version circulated, APPROVED. COMPLETED.	
111/14 – Proposal for the use of NOACS for cardioversion. Approved Red for cardioversion. Secondary care to supply quantity needed for treatment for cardioversion. Patients will then discuss options for future treatment with their GP depending upon the outcome of Cardioversion. APPROVED. COMPLETED.	
114/14 - Bring proposal for dementia patients reviews as part of the SCG ONGOING.	HH
134/14 – Draft a statement about the second line use of anti-TNFs for psoriatic arthritis in line with the decision of the IFR panel. APPROVED – to be added to Blueteq	LA
15/15- Nabilone Change RAG status to BLACK. NCUHT to create a plan to reduce prescribing to current patients	BG
16/15 Generic Prescribing Statement Approved – statement to be added to NECS MO website. COMPLETED.	
20/15 – Sick Day Medication To be removed until national guidance is produced- CLOSED	
21/15 – Mycophenolate mofetil SCG APPROVED. COMPLETED.	
33/15 - NICE CG Medicines Optimisation Base line assessment to be completed by all Trusts for October APC meeting. ONGOING.	ALL
34/15 – Contract Monitoring COMPLETED.	
38/15 – PDE5 Inhibitors for Erectile Dysfunction Requested amendments made. COMPLETED	
52/15 – Topical Ketoprofen Message added to ScriptSwitch. COMPLETED	
54/15 - NTAG-Rituximab for Immune ThrombocytopenicPurpura LA to seek information on position in other NE CCG's. ONGOING	LA

56/15 – Pentosan Polysulfate – RAG Classification

Amendment made to RAG list. COMPLETED.

57/15 – Prescribing of Sevelemar & Lanthanum, Primary or Secondary Care?

RAG status remain RED - COMPLETED

05/15 Cumbria COPD treatment guide

Requested amendments made. APPROVED . COMPLETED.

70/15 **RECENT LJF NEW DRUG RECOMMENDATIONS**

Alprostadil Cream – Treatment of men > 18 years of age with erectile dysfunction who cannot receive or do not tolerate oral PDE5 inhibitors – GREEN

RECENT LJF AMENDMENTS

Allergic emergencies – Emerade, noted, no changes to current prescribing are proposed - GREEN

Magnesium Supplements – Magnaspartate – licensed preparation - GREEN

71/15 **NICE TECHNOLOGY APPRAISALS**

TA345 Naloxegol – Deferred

TA346 Aflibercept – Treatment of diabetic macular oedema – RED

TA347 Nintedanib – For previously treated locally advanced metastatic or locally recurrent non-small-cell lung cancer - RED

TA348 Everolimus – Preventing organ rejection in liver transplantation – Not recommended for new patients.

TA349 Dexamethasone intravitreal implant – Treatment of diabetic macular oedema – RED

TA350 Secukinumab – For treating moderate to severe plaque psoriasis – RED

72/15 **NICE CLINICAL GUIDELINES**

NG12 Suspected Cancer: Recognition and referral – No specific medicines recommendations. NOTED.

NG13 Workplace policy and management practices to improve the health and well-being of employees – No specific medicines recommendations. NOTED.

NG14 Melanoma: assessment and management – Review Current Vitamin D guidelines to ensure NG14 is followed.

LA

73/15 **MEDICINES SAFETY**

Medicines safety officers to meet in September. BG to report to next meeting.

CLINICAL MATTERS

- 74/15 **NTAG – Infliximab Biosimilars – Inflectra and Remsima** – The APC support the & recommendation that the use of Infliximab biosimilars is an option where the originator product (Remicade) would normally be prescribed. BG & AL to review patient numbers prior to considering a managed therapeutic switch programme. **BG,AL,PB**
- 61/15
- 75/15 **NTAG – Omnipod continuous subcutaneous insulin infusion pump system (medical device)** – The committee supported the recommendation for consistency across Cumbria and the NE.
- 76/15 **NTAG – Teriparatide for the treatment of atypical fractures** – The recommendation was supported, not approved for use - BLACK
- 77/15 **Dosulepin prescribing guidance** – APPROVED for use. ENDORSED.
- 78/15 **Drugs for dementia – Prescribing review :**
Recommendation 1 – APPROVED, the drug of lowest acquisition costs (Donepezil) should be prescribed 1st line, Rivastigmine should be prescribed 2nd line.
Recommendation 2 - APPROVED – Memantine in combination with AChE inhibitors - RAG status RED
Recommendation 3 – REJECTED in line with Generic Prescribing Statement
Work with CPFT to facilitate appropriate choice of agent.
- 79/15 **NHS England Letter July 15 –Use of medication in people with learning disabilities** – HH to share bench marking audit with the group and bring to next meeting **HH**
- 80/15 **Denosumab 120mg – Proposal for shared care** – Clinically APPROVED – further financial discussions needed. Current RAG status remains RED. COMPLETED
- 81/15 **Midrodrene – Review of RAG rating** – ONGOING – to be brought to next meeting **PB**
- 82/15 **Review of off-label use of Fludrocortisone for Orthostatic Hypotension** – Review next meeting; PB to check NICE evidence review - ONGOING **PB**
- 83/15 **Enoxaparin Shared Care Guidelines V2** – APPROVED.
- 84/15 **Ciclosporin Shared Care Guideline** – ONGOING to be brought back to next meeting **PB**
- 85/15 **Liothyronine evidence review** – BLACK for new patients pending review, request comments from Consultants. ONGOING **LA PB**
- 86/15 **Avanafil formulary submission** – No decision to be made until decision from SMC (September 2015)
- 87/15 **Metolazone for Heart Failure** – Now unlicensed – RED in North Lancs, secondary care to prescribe in South Cumbria and Lancashire – RAG status RED
- 89/15 **Commissioned Service for adult ADHD in Cumbria** – AL & HH to review **AL, HH**
-

90/15 **Apremilast Memorandum of Understanding** – As minutes of previous meeting, decision endorsed

65/15 **OPERATIONAL**

91/15 **DRUG SAFETY UPDATE**

Drug Safety Update (June 2015) – Add to prescription pad **LA**

Drug Safety Update (July 2015) - Add to prescription pad **LA**

92/15 **FOR INFORMATION**

Minutes received:

NTAG (June 2015) – No comments

NTAG (April 2015) – No comments

Lothian Formulary Committee – LA to attend

93/15 **ANY OTHER BUSINESS**

Just in Case drug authorisation form – new drug added, Judi Matthews to attend next meeting to update and submit a formal request for branded prescribing of Oxycodone. **JM**

DATE and TIME of next meeting

Thursday, 15th October 2015, 2pm at Penrith Rugby Club
